1. Generics Bulletin
  2. >>Archive

Mylan gets October date for US Advair

The US Food and Drug Administration (FDA) has assigned Mylan a revised goal date for regulatory action on the firm’s generic Advair (fluticasone/salmeterol) dossier in mid-October. That date is three months after the company in mid-July this year responded to a complete response letter (CRL) that the FDA had sent towards the end of June, around the time of the 27 June previous target action date for Mylan’s application (Generics bulletin, 22 June 2018, page 1).

The US Food and Drug Administration (FDA) has assigned Mylan a revised goal date for regulatory action on the firm’s generic Advair (fluticasone/salmeterol) dossier in mid-October. That date is three months after the company in mid-July this year responded to a complete response letter (CRL) that the FDA had sent towards the end of June, around the time of the 27 June previous target action date for Mylan’s application (Generics bulletin, 22 June 2018, page 1).

Stressing that the CRL had “only included labelling and chemistry, manufacturing and controls (CMC) comments”, Mylan’s president, Rajiv Malik, told investors that the company had been able to respond quickly...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Generics Bulletin, or if you love it how it is, now is the time to have your voice heard.

Is Towa’s Guidance For 2024 ‘Somewhat Mediocre?’

 
• By Dean Rudge

Bringing in sales that translated to nearly $1.5bn last year, Japan’s Towa was feeling upbeat after a challenging few years, both for itself and the broader Japanese generics market. However, its financial guide for the next 12 months has left investors feeling cold.

Publisher’s Spotlight: Citeline News And Insights App

 
• By Generics Bulletin Team

Introducing the all-new Citeline News and Insights app, providing seamless access to all your favorite award-winning publications. Explore the latest articles from Pink Sheet, Scrip, In Vivo, Medtech Insight, Generics Bulletin and HBW Insight, all in one stylish, intuitive and user-friendly platform.

More from Generics Bulletin

SteinCares Deal Leads Lupin’s Ranibizumab Into Latin America

 
• By Dave Wallace

Lupin is planning to make inroads into the Latin American biosimilars market through a deal with local player SteinCares for a ranibizumab rival to Lucentis.

Hikma Gears Up To Enter US Biosimilars Market With Ustekinumab Nod

 
• By Dave Wallace

Hikma is set to make its first launch into the competitive US biosimilars market after its Bio-Thera-partnered Stelara rival, Starjemza, was approved by the FDA.

Regulatory Recap: ICH To Determine The Future Of Biosimilar Comparative Efficacy Studies

 
• By Urtė Fultinavičiūtė

Generics Bulletin reviews global regulatory developments across the world.